Support and sources

We point to organisations and published sources we trust. igg4.org is independent, with no industry funding or sponsor. A mention here is a credit, not a gatekeeper.

Key medical literature

The published sources behind this site. Where possible we link to a version you can read in full; otherwise to the publication record. This is information and does not replace your specialist.

1.Della-Torre E, Talarico R, Ballarin J, et al. The five red flags for IgG4-related disease. The Lancet Rheumatology, 2025.
Read source
2.Wallace ZS, Naden RP, Chari S, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis & Rheumatology, 2020.
Read source
3.Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatology Advances in Practice, 2024.
Read source
4.Iaccarino L, Talarico R, Scire CA, et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019.
Read source
5.Sina S, Bonisoli GL, et al. Clinicopathological pearls and diagnostic pitfalls in IgG4-related disease. Diagnostics, 2025.
Read source
6.Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology, 2020.
Read source
7.Abraham M, Khosroshahi A. Diagnostic and treatment workup for IgG4-related disease. Expert Review of Clinical Immunology, 2017.
Read source
8.Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis & Rheumatology, 2015.
Read source
9.Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. New England Journal of Medicine, 2025.
Read source
10.Cagnotto G, Backlund RT, Bengtsson A, Bruschettini M. Immunosuppressants for IgG4-related disease (protocol). Cochrane Database of Systematic Reviews, 2025.
Read source
11.Cuéllar MC, et al. Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos. Rev Med Chile 2022;150:705-710.
Read source
12.Martínez Calabuig P, et al. Enfermedad relacionada con IgG4: revisión de casos diagnosticados entre 2010-2021. Rev. Sociedad Val. Reuma. 2022;8(5):4-10.
Read source
13.Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford) 2020;59:2435-2442.
Read source
14.Okazaki K (ed.). IgG4-Related Disease. Current Topics in Microbiology and Immunology, vol. 401. Springer International Publishing, 2017.
Read source
15.Orozco Gálvez O. Enfermedad relacionada con la IgG4: creación de un algoritmo diagnóstico y terapéutico europeo y nuevas técnicas de medicina nuclear. Doctoral thesis, Universitat Autònoma de Barcelona, 2024.
Read source
16.Bateman AC, Culver EL. Challenges and pitfalls in the diagnosis of IgG4-related disease. Seminars in Diagnostic Pathology, 2023.
Read source
17.Reisch M, Spindelböck WJ, Hodl I, et al. Azathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature. Rheumatology International, 2026.
Read source
18.González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach. J Clin Med 2025;14(19):6774 (literature searched through July 2025).
Read source
19.Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, Vaglio A. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol 2025;21(5):275-290.
Read source
20.Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025;64(Suppl 1):i24-i27.
Read source
21.Arias-Intriago M, Gomolin T, Jaramillo F, et al. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. Int J Mol Sci 2025;26(11):5325.
Read source
22.Khurram SA, Gueiros LAM, Soares CD, Fonseca FP. IgG4-Related Disease. In: Lymphoproliferative and Granulomatous Disorders of the Oral Cavity. Springer, 2025:207-213.
Read source
23.Hao Q, Lian D, Zhou M, et al. Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease. Arthritis Res Ther, 2026.
Read source
24.Stone JH, et al. Obexelimab for IgG4-related disease (INDIGO trial). N Engl J Med, published online 2 June 2026.
Read source
25.Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-1913.
Read source
26.Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013.
Read source
27.Nuthalapati M, Menon AR, Rajendran R, et al. IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies. Indian J Surg Oncol 2025;16(6):1446-1451.
Read source
28.Tomkins M, Martin-Grace J, Kennedy C, et al. Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrol Dial Transplant 2023;38(2):236-245.
Read source

National clinical guidance

The links below point outside this site, to help you look further on your own. We do not control or endorse them, and we gain nothing from listing them. Unlike our own sources above, these are not checked by us for origin or accuracy. Always confirm anything important with your specialist.

1.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4, Haute Autorite de Sante, FAI2R and CERAINOM-IgG4, November 2025.
Read source

Product information (regulatory)

1.Ficha técnica prednisona, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA
Read source

Useful websites

Behind this project: our book, Balanced Divinity